what-when-how
In Depth Tutorials and Information
GENETIC TESTING AND COUNSELING
IN OI
[5] Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, et al. A single
recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis
imperfecta type V. Am J Hum Genet 2012;31(2):343-8.
[6] Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K,
Aktas D, et al. Mutations in the gene encoding the RER protein
FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am
J Hum Genet 2010;86(4):551-9.
[7] Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S,
et  al. Prolyl 3-hydroxylase 1 deiciency causes a recessive meta-
bolic bone disorder resembling lethal/severe osteogenesis imper-
fecta. Nat Genet 2007;39(3):359-65.
[8] van der Slot AJ, Zuurmond AM, Bardoel AF, Wijmenga C,
Pruijs HE, Sillence DO, et al. Identiication of PLOD2 as telopeptide
lysyl hydroxylase, an important enzyme in ibrosis. J Biol Chem
2003;278(42):40967-72.
[9] van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR,
Fratantoni SA, et  al. PPIB mutations cause severe osteogenesis
imperfecta. Am J Hum Genet 2009;85(4):521-7.
Although a diagnosis of OI can be made based on
clinical and radiologic findings, genetic testing is impor-
tant to determine the inheritance pattern. In some fami-
lies, it may be impossible to determine the inheritance
pattern just based on the pedigree. For example, a pedi-
gree with only a single affected individual could rep-
resent a recessive form, or the individual could have a
de novo dominant mutation. A pedigree showing only
affected siblings would appear to be recessive, but the
recurrence could also be due to parental mosaicism for a
dominant mutation. Therefore, when possible, molecu-
lar testing should be performed to definitely determine
the inheritance pattern. This will allow accurate genetic
counseling in terms of recurrence risk and enable repro-
ductive options such as preimplantation genetic diagno-
sis and prenatal testing (see Chapter 26).
Genetic testing in an index case should begin with
sequencing of COL1A1 and COL1A2 genes, followed
by quantitative analysis to detect whole-gene and exon-
level deletions and duplications. If no alterations of
COL1A1 or COL1A2 are found and the clinical diagnosis
is accurate, testing should proceed to include the reces-
sive genes. With this approach, it is estimated that caus-
ative mutation(s) will be found in greater than 98% of
patients with OI. 15
Although the importance of genetic testing to deter-
mine inheritance pattern and recurrence risk cannot be
overemphasized, ultimately the classification of OI (e.g.,
types I-IV) is a clinical one (see Chapter  2). There may
be some correlations between genotype and phenotype,
as discussed in the following chapter, but these are not
always generalizable and exceptions may occur. This
can be a confusing issue for families and should be clar-
ified by thorough genetic counseling. Genetic counsel-
ors can help families understand the genetic test results
in the context of the patient's clinical presentation.
[10]
Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et  al.
Exome sequencing identiies truncating mutations in human
SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am
J Hum Genet 2011;88(3):362-71.
[11]
Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi
M, Alrasheed S, et  al. Homozygosity for a missense mutation
in SERPINH1, which encodes the collagen chaperone protein
HSP47, results in severe recessive osteogenesis imperfecta. Am J
Hum Genet 2010;86(3):389-98.
[12]
Lapunzina P, Aglan M, Temtamy S, Caparrós-Martín JA,
Valencia M, Letón R, et  al. Identiication of a frameshift muta-
tion in Osterix in a patient with recessive osteogenesis imper-
fecta. Am J Hum Genet 2010;87(1):110-4.
[13]
Shaheen R, Alazami AM, Alshammari MJ, Faqeih E, Alhashmi N,
Mousa N, et al. Study of autosomal recessive osteogenesis imper-
fecta in Arabia reveals a novel locus deined by TMEM38B muta-
tion. J Med Genet 2012;49(10):630-5.
[14]
Fahiminiya S, Majewski J, Mort J, Moffatt P, Glorieux FH, Rauch F.
Mutations in WNT1 are a cause of osteogenesis imperfecta. J Med
Genet 2013;50(5):345-8.
[15]
van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A,
Rohrbach M, et al. EMQN best practice guidelines for the labo-
ratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet
2012;20(1):11-19.
[16]
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteo-
genesis imperfecta. J Med Genet 1979;16(2):101-16.
[17]
Young ID, Harper PS. Recurrence risk in osteogenesis imper-
fecta congenita. Lancet 1980;1(8165):432.
[18]
Byers PH, Tsipouras P, Bonadio JF, Starman BJ, Schwartz RC.
Perinatal lethal osteogenesis imperfecta (OI type II): a biochemi-
cally heterogeneous disorder usually due to new mutations in
the genes for type I collagen. Am J Hum Genet 1988;42(2):237-48.
References
[1] Nussbaum RL, McInnes RR, Willard HF. Thompson and
Thompson Genetics in Medicine, 6th ed. Saunders; 2004.
[2] Pepin M, Atkinson M, Starman BJ, Byers PH. Strategies and
outcomes of prenatal diagnosis for osteogenesis imperfecta: a
review of biochemical and molecular studies completed in 129
pregnancies. Prenat Diagn 1997;17(6):559-70.
[3] Martínez-Glez V, Valencia M, Caparrós-Martín JA, Aglan M,
Temtamy S, Tenorio J, et al. Identiication of a mutation causing
deicient BMP1/mTLD proteolytic activity in autosomal reces-
sive osteogenesis imperfecta. Hum Mutat 2012;33(2):343-50.
[4] Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M,
et al. CRTAP is required for prolyl 3-hydroxylation and mutations
cause recessive osteogenesis imperfecta. Cell 2006;127(2):291-304.
[19]
Pyott SM, Pepin MG, Schwarze U, Yang K, Smith G, Byers PH.
Recurrence of perinatal lethal osteogenesis imperfecta in sib-
ships: parsing the risk between parental mosaicism for domi-
nant mutations and autosomal recessive inheritance. Genet Med
2011;13(2):125-30.
[20]
Bodian DL, Chan TF, Poon A, Schwarze U, Yang K, Byers PH,
et  al. Mutation and polymorphism spectrum in osteogenesis
imperfecta type II: implications for genotype-phenotype rela-
tionships. Hum Mol Genet 2009;18(3):463-71.
[21]
Cabral WA, Barnes AM, Adeyemo A, Cushing K, Chitayat
D, Porter FD, et  al. A founder mutation in LEPRE1 carried
by 1.5% of West Africans and 0.4% of African Americans
causes lethal recessive osteogenesis imperfecta. Genet Med
2012;14(5):543-51.
 
Search WWH ::




Custom Search